A recent study reveals that individuals who stop using new weight-loss injections like semaglutide or tirzepatide can put back on reduced body mass at a significantly accelerated pace than those who stop traditional diet and exercise regimens.
Published data in a prominent medical journal demonstrates that while obese people can lose substantial amounts of their total mass while on the medication, the weight is regained at an estimated rate of nearly a kilo each month upon discontinuation.
"People purchasing such drugs must be informed of the potential of quick rebound weight gain when the treatment is stopped," cautioned expert Dr. Susan Jebb.
That rate of recovery suggests a reversion to original weight in about one and a half years.
Analyzing Approaches
The study, which looked at 37 of studies involving thousands of patients, compared the outcomes of these new drugs with conventional dieting.
The team point out that individuals who shed pounds through diet and exercise typically have a more gradual creep back—approximately 0.1 kg a month—post-intervention.
Understanding the Fast Rebound
Experts believe the mechanism of the drugs accounts for the heightened regain.
GLP-1 drugs copy a natural hormone called glucagon-like peptide-1, which controls feelings of fullness.
"Sustained high doses of the hormone concentrations several times higher than the body's typical production may cause the system to generate a reduced amount of its own natural hormone, and may also diminish sensitivity to its effects," said Dr. Adam Collins, a nutrition researcher.
"Discontinuation of this medication leads to hunger is unsuppressed, making excessive eating far more likely."
A Chronic Disease?
Medical guidelines suggest the jabs for individuals with weight-linked medical conditions, alongside recommended diet and exercise modifications.
A number of clinicians argue that, given the likelihood of relapse, the therapy should be considered life-long.
This perspective is supported by pharmaceutical companies, who state that the findings "highlight the persistent character of excess weight," comparing it to managing conditions like high blood pressure.
Patient Testimonies
People who have come off the jabs report a powerful resurgence of hunger.
"It felt as if a trigger that goes on and you're instantly starving," said one woman.
This challenge is worsened if individuals have not developed permanent dietary or behavioural modifications during treatment.
Significant Use
Figures suggest that millions of adults in the UK have tried these injections in the last 12 months, with interest continuing to grow.
- Use is more common among females than males.
- The middle-aged age group shows the greatest level of interest.
- A large proportion access the drugs through private prescriptions rather than the NHS.
In conclusion, researchers stress that while GLP-1 drugs are effective tools for weight loss, they are not a standalone fix and lasting health benefits hinges on combined behavioural management.
